Elagolix - Latest Advances

New perspectives in managing chronic pelvic pain in Endometriosis: the role of GnRH antagonists versus dienogest.

Journal: Expert opinion on pharmacotherapy

Published: April 10, 2026

Safety of 48 months of elagolix with add-back therapy for endometriosis-associated pain.

Journal: AJOG global reports

Published: January 08, 2026

Single-Dose Bioequivalence Study of Elagolix Tablets 200 mg (Test Product) and Elagolix Tablets 200 mg (Reference Product) in Healthy Non-Pregnant, Non-Lactating Premenopausal Female Subjects Under Fasting Conditions.

Journal: Clinical pharmacology in drug development

Published: December 18, 2025

Bone mineral density with elagolix plus add-back therapy in women with heavy menstrual bleeding and uterine fibroids: open-label and post-treatment results of a 60-month phase 3 trial.

Journal: AJOG global reports

Published: December 01, 2025

Atypical gelation of Elagolix sodium in aqueous media: Mechanistic insights and Inhibition via coamorphization.

Journal: European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V

Published: October 15, 2025

Insights on Medical Therapy for Uterine Fibroids: A Review.

Journal: Advances in therapy

Published: September 12, 2025

Efficacy of Elagolix and Relugolix for the Treatment of Pelvic Pain in Patients With Endometriosis: A Systematic Review.

Journal: Cureus

Published: September 12, 2025

Comparison of Letrozole with Elagolix for the Management of Endometriosis-Associated Pain: A Quasi-Experimental Study.

Journal: Journal of the College of Physicians and Surgeons--Pakistan : JCPSP

Published: September 05, 2025

Efficacy and tolerability of elagolix in adolescents and young adults with endometriosis: a small, single-center retrospective cohort study.

Journal: Journal of pediatric and adolescent gynecology

Published: September 02, 2025

Elagolix as a Diagnostic and Therapeutic Bridge to Surgery in Refractory Progestogen Hypersensitivity.

Journal: JCEM case reports

Published: August 06, 2025

Identifying Bioactive Conformation of GnRH1 Based on Molecular Docking of NMR Conformers to GnRH1R and mAbs.

Journal: Proteins

Published: June 28, 2025

CalOPT: A Specialty Pharmacy-Dietitian Quality Improvement Initiative for Calcium Optimization in Patients with Osteoporosis Risk.

Journal: Pharmacy (Basel, Switzerland)

Published: April 22, 2025